Cameo
Well-differentiated squamous cell carcinoma of the penis
associated with HPV type 33
Paolo Amerio, MD, Annamaria Offidani, MD, Andreina Cellini, MD,
and Guido Bossi, PhD
From the Clinica Dermatologica,
Università degli Studi di Ancona,
Ancona, Italy
A 70-year-old Caucasian widower, who was a heavy smoker and negligent in his personal
Correspondence
Annamaria Offidani, MD
Clinica Dermatologica
Ospedale Umberto I
P.zza Cappelli 1
60100 Ancona
Italy
examination, an irregular, oval-shaped (3 cm 3 2 cm) ulcer was observed that extended
care, but apparently in good general condition, come to our attention in November 1994.
He referred to the onset, about 5 months previously, of a genital ulcer. On clinical
from the glans to the coronal sulcus (Fig. 1). The fundus of the lesion was reddish, the
margins were prominent, and indurated. A palpable lymph node of 1 cm in diameter was
present in the left inguinal region, while the other superficial nodes were clinically normal.
The medical history and laboratory examinations were otherwise unremarkable.
Pathologic examination showed a well-differentiated squamous cell carcinoma, partly
‘‘in situ ’’ (Fig. 2A) and partly infiltrating the deeper structures (Fig. 2B) with a maximal
thickness of 0.6 cm. No Bowenoid-type differentiation was seen.
The carcinoma specimen, analyzed by flow cytometry, revealed the presence of one
cellular diploid population.
The patient was transferred to the Urologic Clinic of our hospital where he underwent
partial penectomy and bilateral inguinal lymphadenectomy. The pathologic report of these
lymph nodes was negative for metastatic lesions.
At 1 year follow-up, the patient was negative for local cancer relapse and inguinal
metastatic lesions at clinical examination.
A polymerase chain reaction (PCR) analysis was performed on DNA from the tumor
specimen, using specific primers complementary to DNA sequences highly conserved
among human papillomavirus (HPV) types 16, 18, 31, 33 and 56. The specimen was
found to be positive for HPV type 33 DNA (Fig. 3).
Discussion
128
Penile carcinoma is an uncommon affection; in the USA and
Europe, it accounts for 0.5% of all human tumors. Generally,
it develops in patients over 60 years of age, and is favored
by poor genital hygiene and chronic irritation in the coronal
sulcus. It has been associated with chronic inflammatory
dermatosis, scars, cigarette smoking, UV radiation, and
human papillomavirus (HPV) infection.
So far, more than 77 distinct HPV types and 30 putative
novel genotypes have been characterized.1 Some, such as
HPV 6, 11, and 42, have usually been associated with benign
genital lesions, e.g. warts and acuminate condylomas, while
others, particularly HPV 16, 18, 31, and 33, have been
associated, especially in women, with the development of
cancer.2
Today, it is generally accepted that one-third to one-half of
the cases of infiltrating carcinoma of the penis are associated
International Journal of Dermatology 1998, 37, 128–144
with HPV.3 HPV types 16 and 18 are the most frequently
associated with penile carcinoma, while other types have
occasionally been found.4
Only a few epidemiologic studies have been carried out
on squamous cell carcinoma of the male genitalia, probably
because of the fairly low prevalence of this disease. In 1994,
Chan et al.5 reported that the prevalence of HPV types 16
and 18 associated with penile squamous cell carcinoma
ranged, in the literature, from 0% to 67%. The authors
observed that the reports considered did not subclassify the
tumors histologically. They applied this classification to their
cases, and pointed out that the subgroup of well-differentiated squamous cell carcinoma was not associated with HPV
types 16 or 18. This observation may suggest the role of
different HPV types in the pathogenesis of well-differentiated tumors.
HPV 33 is regarded as an HPV of intermediate oncogenic
risk. Cell lines transfected with HPV 33 became immortal© 1998 Blackwell Science Ltd
Amerio et al.
Squamocellular carcinoma Cameo
Figure 1 Wide painless ulceration on the glans extending to
the coronal sulcus
Figure 3 PCR results demonstrating the presence of HPV
type 33 DNA in the tissue specimen
ized, and in vitro reconstituted epithelia with these cell lines
acquired the characteristics of cervical intraepithelial neoplasia grade III lesions.6 These phenomena cannot be strictly
related to HPV 33 infection alone; more probably, a second
event is necessary for the transformation into carcinomas.1
We believe that, in our case of well-differentiated squamous cell carcinoma, other cofactors, such as cigarette smoking and poor hygiene, could have contributed, together with
HPV 33 infection, to the development of the tumor. Moreover, the follow-up after conservative surgery showed a
benign course with no relapse; this observation was consistent with the positive prognostic factors for survival in our
patient.7 We wish to stress the importance of HPV subtype
characterization and the early diagnosis and prognostic
evaluation of pre-cancerous and cancerous lesions of the
male genitalia.
References
Figure 2 Well-differentiated squamocellular carcinoma: (a)
partly ‘‘in situ’’; (b) partly infiltrating the deeper structures
© 1998 Blackwell Science Ltd
1 zur-Hausen H. Papillomavirus infections—a major cause
of human cancer. Biochim Biophys Acta 1996; 1288: F55–
F78.
2 Verdon ME. Issues in the management of human
papillomavirus genital disease. Am Fam Physician 1997;
55: 1813–1816.
3 Cubilla AL. Carcinoma of the penis. Mod Pathol 1995; 8:
116–118.
International Journal of Dermatology 1998, 37, 128–144
129
130
del Pozo et al.
Cameo Flexural purpura
4 Cupp MR, Malek RS, Goellner JR, et al. The detection
of human papillomavirus deoxyribonucleic acid in
intraepithelial, in situ, verrucous and invasive carcinoma
of the penis. J Urol 1995; 154: 1024–1029.
5 Chan KW, Lam KY, Chan ACL, et al. Prevalence of
human papillomavirus types 16 and 18 in penile
carcinoma: a study of 41 cases using PCR. J Clin Pathol
1994; 47:
823–826.
6 Gilles C, Piette J, Peter W, et al. Differentiation ability
and oncogenic potential of HPV-33– and HPV-331rastransfected keratinocytes. Int J Cancer 1994; 58: 847–854.
7 Lindegaard JC, Nielsen OS, Lundbeck FA, et al. A
retrospective analysis of 82 cases of cancer of the penis.
Br J Urol 1996; 77: 883–890.
Cameo
Flexural purpura and Epstein–Barr virus infection
Jesús del Pozo, MD, Manuel Almagro, MD, Jesús Garcı́a-Silva, MD, Walter Martı́nez, MD,
and Eduardo Fonseca, MD
From the Department of Dermatology,
Hospital Juan Canalejo, La Coruña,
Spain
A 38-year-old woman presented with flexural lesions of 4 days duration, accompanied by
Correspondence
Jesús del Pozo, MD
Servicio de Dermatologı́a
Hospital Juan Canalejo
Xubias de Arriba, 84
La Coruña
Spain
selective way, the axillary folds (Fig. 1), the elbow flexures, and the inguinal (Fig. 2) and
perianal areas. Inflammatory laterocervical and submandibular lymphadenopathy was
noted.
pruritus in her hands, arthralgia, sore throat, and a 38 °C fever. Examination revealed
macular purpuric lesions with a tendency to be grouped into plaques that affected, in a
Histopathologic examination showed a normal epidermis and a perivascular lymphocytic
infiltrate in the papillar dermis, consisting of eosinophils and extravasated red cells.
Vasculitis and other signs of vascular damage were not observed. A Congo red stain was
negative.
Laboratory tests showed moderate lymphocytosis with 2% atypical lymphocytes and
mild elevation of serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic
pyruvic transaminase (SGPT). Coagulation studies, urinalysis, immunoglobulins, and
serum electrophoresis were normal. Cryoglobulins were negative. Serology for
cytomegalovirus (CMV), toxoplasma, rubella, and human parvovirus B19 showed findings
of past infection. Serology for A, B and C hepatitis virus was negative. Mono-spot test
was negative and the Epstein–Barr virus (EBV specific antibody response is shown in
Table 1. The standard True-test was negative.
The clinical manifestation cleared spontaneously within 15 days.
Discussion
The Epstein–Barr virus (EBV) is a lymphotrophic human
herpes virus with a biology similar to its homologs in the
herpes family, because it infects humans through a primary
infection and further reactivation.1 Primary infection by
EBV usually occurs during early childhood and is asymptomatic. In developed countries, its delay is frequently to
later childhood, adolescence, or young adults, showing a
more severe clinical presentation.2 EBV reactivations have
been associated with several diseases, such as hematologic
International Journal of Dermatology 1998, 37, 128–144
neoplasia, nasopharyngeal carcinoma, and oral hairy leukoplakia.3
From the first clinical description of infectious mononucleosis in 1920, and its etiologic association with EBV in
1968, the recognized cutaneous manifestations of infection
with this type of human herpes virus have increased.4
Currently, we can classify them into three groups (Table 2):
(1) dermatologic manifestations associated with primary infection, which may be expressed as infectious
mononucleosis (IM) or Gianotti–Crosti syndrome; (2)
© 1998 Blackwell Science Ltd
del Pozo et al.
Flexural purpura Cameo
Table 1 Serologic evolution of EBV infection in our patient
Anti-VCA
Anti-EBNA
IgG
IgM
IgG
Sept 1995
Nov 1995
Mar 1996
1
1
–
1
–
1
1
–
1
VCA, viral capsid antigen; EBNA, EBV-determined nuclear
antigen; IgG, immunoglobulin G; IgM, immunoglobulin M.
Table 2 Cutaneous manifestations of Epstein–Barr virus
infection (modified from Baldari et al.4)
(1) During the course of infectious mononucleosis (primary infection)
d Exanthem
d Exanthem induced by antibiotics
d Acute urticaria and cold urticaria
d Acrocyanosis
d Palmar dermatitis
d Erythema multiforme
d Erythema nodosum
d Erythema annulare centrifugum
d Pityriasis lichenoides
d Granuloma annulare-like eruption
d Lipschütz’s ulcer
d Flexural purpura
Or Gianotti–Crosti syndrome (primary infection)
(2) Mucous manifestations
d Petechiae on the palate (primary infection or reactivation)
d Oral hairy leukoplakia (reactivation)
(3) Other associations with cutaneous involvement (reactivations)
d Hemophagocytic syndrome in childhood
d Bullous pemphigoid
d Cutaneous vasculitis
d Kawasaki-like disease
d Secondary Sjogren syndrome
d Pseudolymphoma, lymphoma, leukemia, and myelodysplastic
syndrome with cutaneous involvement
d Histiocytic cytophagic panniculitis
Figure 1 Purpuric papules on the axillary folds
© 1998 Blackwell Science Ltd
Figure 2 Lesions grouped into purpuric plaques on the
inguinal folds
mucous manifestations; (3) features that usually appear
during the course of hematologic neoplasia or in immunosuppressed patients.
The exanthems that appear during the primary infection
are usually directly related to EBV, although some antibiotics may play an inductor role in their pathogenesis. A
wide clinical morphology for these exanthems has been
described, including morbilliform, roseolliform, rubelliform, urticarial, and rarely generalized purpuric eruptions.5
Several viral diseases, such as enteroviral infection, Band C-type hepatitis, rubella, measles, human parvovirus
B19, and EBV infection, may produce purpuric lesions,6
but in no case with a distribution exclusively located on
the folds.
Purpuric features associated with EBV infection, previously described, include morbilliform purpuric exanthem
as IM manifestation,7 cutaneous vasculitis as initial feature
of myeloproliferative syndrome,8 palatal petechiae in both
primary infection and reactivation phases,1 and disseminated small purpuric lesions in immunosuppressed patients.9
International Journal of Dermatology 1998, 37, 128–144
131
132
Hizli, Özdemir, and Bakkaloǧlu
Cameo Anhidrotic ectodermal dysplasia
Our patient had a self-limiting process, characterized by
a sore throat, fever, arthralgia, lymphadenopathy, and
exanthem, which was clinically compatible with a virosis.
We have discarded the main viral diseases that cause
purpuric exanthem and other causes of purpura. The
serologic findings clearly demonstrated a primary infection
by EBV. Therefore, we believe that, in our case, the flexural
purpura was an unusual manifestation of primary EBV
infection.
To our knowledge, flexural purpura has not previously
been reported in relation to EBV infection. Because EBV
is so ubiquitous, the observation of a new manifestation
of EBV infection might seem unusual. Nevertheless, because
primary EBV infection is a self-limiting process, an adequate
study is not made in most cases, and uncommon features
may be overlooked.
Although more reports will be necessary to verify this
atypical presentation, we believe that a primary EBV
infection should be investigated in patients with flexural
purpura.
2
3
4
5
6
7
8
9
References
1 Schooley RT. Epstein–Barr virus (infectious
mononucleosis). In: Mandell GL, Douglas RG, Bennett
JE, eds. Principles and Practice of Infectious Diseases.
New York: Churchill Livingstone, 1995: 1364–1377.
Hogan PA, Morelli JG, Weston WL. Viral exanthems.
Curr Probl Dermatol 1992; 59–63.
Niederman JC. Epstein Barr virus infections. In:
Fitzpatrick TB, Eisen AZ, Wolff K, eds. Dermatology
in General Medicine, 4th edn. New York: McGrawHill, 1993: 2581–2586.
Baldari U, Cancellieri C, Celli B, et al. Skin disorders
and Epstein Barr virus primary infection: results of a
31 month survey. J Eur Acad Dermatol Venereol 1995;
4: 239–247.
Caussade P, Katz JC, Heid GE. Infection humaine a
virus Epstein Barr (VEB). Manifestations
dermatologiques. Ann Dermatol Venereol 1987; 114:
289–300.
Scholssberg D. Fever and rash. Infect Dis Clin North
Am 1996; 10: 101–110.
Milne J. Infectious mononucleosis. N Engl J Med 1945;
233: 727.
Tsai TF, Chen RL, Su IJ, et al. Epstein Barr virusassociated lymphoproliferative disorder of granular
lymphocytes presenting initially as a cutaneous
vasculitis. J Am Acad Dermatol 1994; 30: 399–444.
Fermand JP, Gozlan J, Bendelac A, et al. Detection of
Epstein Barr virus in epidermal lesions of an
immunocompromised patient. Ann Int Med 1990; 112:
511–515.
Cameo
Anhidrotic ectodermal dysplasia (Christ–Siemens–Touraine
syndrome) presenting as a fever of unknown origin in an
infant
Şamil Hizli, MD, Sila Özdemir, MD, and Ayşun Bakkaloǧlu, MD
From the Hacettepe University
Medical Faculty, Ankara, Turkey
Correspondence
Şamil Hizli, MD
Hacettepe University Medical Faculty
Ihsan Dogramaci Cocuk Hastanesi
Samanpazari
Ankara
Turkey
A 16-month-old boy (Fig. 1) was referred to the Department of Pediatrics, University
Hospital of Hacettepe, in February 1997, suffering from recurrent fever and inability to
sweat. His history revealed repeated otitis media and rhinitis, together with dry skin and
heat intolerance. Lacrimation was also lacking. His parents were not relatives and both of
them were healthy.
On physical examination, his weight was below the third percentile for length; the
patient was irritable, but normal in view of mental development. His skin (Fig. 2) was
smooth, dry, and pale. Subcutaneous fat was scanty and vessels were easily visualized.
His nails, palms, and soles were normal, his scalp hair was sparse, fragile, and extremely
blonde, and his eyebrows and eyelashes were lacking. His nose was saddled. Anodontia
was present, and ortopantography revealed that only one canine at each side of the
mandible and two canines at the upper jaw were present, and were conical in shape
(Fig. 3). The ears were pointed and low set.
International Journal of Dermatology 1998, 37, 128–144
© 1998 Blackwell Science Ltd
Hizli, Özdemir, and Bakkaloǧlu
Anhidrotic ectodermal dysplasia Cameo
Discussion
Thurnam in 1848 described a most frequent, well-recognized form of anhidrotic ectodermal dysplasia (Table 1)
known as the Christ–Siemens–Touraine syndrome.1 It is
characterized by hypotrichosis, hypodontia, and absence
of eccrine sweating.2 Pathogenetically, ectodermal dysplasia
is hypothesized to be a developmental delay defect which
prenatally affects the ectoderm and is inherited as an Xlinked recessive trait.3 A clinically identical autosomal
recessive form has also been described.4 Recurrent fevers,
at times quite high, can be the presenting symptom, leading
to unnecessary diagnostic tests. This diagnosis may go
unrecognized in a patient presenting with a fever of no
apparent origin if anhidrotic ectodermal dysplasia is not
considered in differential diagnosis. The incidence of ectodermal dysplasia is unknown. The men : women ratio is
5 : 1.5,6 Affected men demonstrate the characteristic signs
of anhidrosis, resulting from the complete absence of
eccrine sweat glands, as well as a partial deficiency of
apocrine glands. Affected women are carriers without
clinical abnormalities.7 Diagnosis is confirmed by skin
biopsy which, as in our case, reveals the absence of
dermal appendages. Eyebrows are scanty or totally absent.
Figure 2 Absence of dermal appendages is confirmatory
(hematoxylin and eosin; original magnification, 3 100)
Table 1 Key features of anhidrotic ectodermal dysplasia
Soft, thin skin
Hypotrichosis
Hyperthermia from inadequate sweating
Dentition abnormalities: anodentia/hypodontia, small, conical or missing
teeth
Small, saddle-shaped nose
Fine, dry, sparse hair, eyebrows
Small, pointed, low set ears
Dystrophic nails
Chronic rhinorrhea
Increased periorbital pigmentation
Figure 3 Abnormal dentition is a frequent finding at X-ray
Figure 1 Photograph of case at 16 months
© 1998 Blackwell Science Ltd
Periorbital pigmentation, a feature not observed in our
case, may present at birth.
Conjunctivitis may present from the lack of lacrimation
and eyelashes, as in this situation. The patient may be
severely photophobic. Our case demonstrated the abnormalities of low set and pointed ears. In addition, he had a
typical low nasal bridge producing a saddle-shaped nose.
Chronic rhinitis is typically present, as in our case. Scalp
International Journal of Dermatology 1998, 37, 128–144
133
134
Jaffe and Heymann
Cameo Kwashiorkor and zinc deficiency
hair is scanty, fine, and fragile, and at times completely
absent. The body hair is sparse. Despite the fact that the
parents may have darkly pigmented hair, the hair color is
blond. The skin is soft, shiny, thin, and wrinkled. The
subcutaneous fat layer is severely thinned, allowing easy
visualization of the subdermal vessels. Dentition is usually
delayed. Abnormalities vary from anodontia to hypodontia
with only one or two normally shaped teeth.8 X-Rays
revealed that our patient had only a few abnormally shaped
teeth. Mental development is most often normal, but
subthreshold cerebral dysrhythmia and mental retardation
have been reported.5,6 The electroencephalogram was normal in our case.
Abnormalities of the gonads and skeletal system may
occur, although in our case laboratory and radiologic
evaluation revealed no such defects.9 The deficiency or
absence of buccal glands in the oral mucosa induces a
susceptibility to infection. A lack of protective secretions
of the oral, nasopharyngeal, and upper respiratory mucosa
tends to induce frequent and sometimes chronic pharyngitis,
bronchitis, rhinitis, and otitis media. Paradoxically, watery
rhinorrhea may occur because of a lack of respiratory
mucus.
Conclusions
The consideration of the diagnosis of anhidrotic ectodermal
dysplasia is critical when evaluating a child presenting with
a fever of unknown origin. The mitigation of fever using
methods such as cold compresses is critical in the newborn
and infant to prevent fluid and electrolyte disturbance,
central nervous system damage, and possible demise from
hyperthermia. Corrective dental measures are the only
therapy available.10 Once the diagnosis is made, the physician should refer the parents and, when the afflicted
individual becomes a young adult, the patient for genetic
counseling.
References
1 Freire-Maia N, Pinheiro M. Ectodermal Dysplasias: A
Clinical and Genetic Study. New York: Alan R. Liss,
1984.
2 Thurnam J. Two cases in which the skin, the hair and
teeth were very imperfectly developed. Proc R Chir Soc
1848; 31: 71.
3 Freire-Maia N. Ectodermal dysplasias revisited. Acta
Genet Med Gemellol 1977; 26: 121–131.
4 Lawrence MS, Keuer EJ. The ectodermal dysplasias. Acta
Dermatol 1980; 116: 1295–1299.
5 Upshaw BY, Montgomery H. Hereditary anhidrotic
ectodermal dysplasia: a clinical and pathological study.
Arch Dermatol Syphilol 1949; 60: 1170–1183.
6 Sunderman FW. Persons lacking sweat glands: a
hereditary ectodermal dysplasia of anhidrotic type. Arch
Intern Med 1941; 67: 846–854.
7 Bartstra HLJ, Hulsmans RFH. Mosaic expression of
hypohidrotic ectodermal dysplasia in an isolated affected
female child. Arch Dermatol 1994; 130: 1421–1424.
8 Everett FG, Jump EB, Sutherland WF, et al. Anhidrotic
ectodermal dysplasia with anodontia: a study of two
families. J Am Dent Assoc 1952; 44: 173–186.
9 Mohler DN. Hereditary ectodermal dysplasia of the
anhidrotic type associated with primary hypogonadism.
Am J Med 1959; 27: 682–688.
10 Weston WL, Lane AT. Textbook of Pediatric
Dermatology. St Louis: Mosby Year Book, 1994: 184–
185.
Cameo
Kwashiorkor/zinc deficiency overlap following partial
gastrectomy
Andrew T. Jaffe, MD, and Warren R. Heymann, MD
From the UMDNJ-Robert Wood
Johnson Medical School at Camden,
Cooper Hospital/University Medical
Center, Marlton, New Jersey
A 48-year-old African–American woman presented with an eruption on her thighs,
buttocks, and upper extremities of approximately 2 months duration. She also complained
of diarrhea, poor appetite, weakness, and pain around her mouth and eyes. Her medical
history was significant for a gastrojejunostomy and stomach stapling for morbid obesity at
the age of 32. The procedures resulted in a 500 lb weight loss over several years (from
600 lb to 106 lb). Her course was complicated by multiple bouts of diarrhea, inanition, and
coma.
International Journal of Dermatology 1997, 37, 128–144
© 1998 Blackwell Science Ltd
Jaffe and Heymann
Kwashiorkor and zinc deficiency Cameo
Correspondence
Warren R. Heymann, MD
UMDNJ-Robert Wood Johnson
Medical School at Camden
Cooper Hospital/University Medical
Center
100 Brick Road
Suite 306
Physical examination demonstrated sharply demarcated plaques of dusky erythema,
with superficial desquamation and a ‘‘cracked enamel’’ appearance, over the upper
Marlton, NJ 08053
levels of magnesium, vitamin B12, folic acid, total iron, glucagon and zinc. Abnormal
laboratory values included total serum protein 5.5 g/dL (normal, 6.0–8.2 g/dL), albumin
2.2 g/dL (normal 3.5–5.0 g/dL), and serum zinc 30 µg/dL (normal, 60–130 µg/dL).
A biopsy from the left hip (Fig. 2) revealed dense parakeratotic scale with an irregularly
extremities, buttocks, and extending to the lateral aspects of the thighs (Fig. 1). Erythema
and crusting were noted at the corners of her mouth, and a few small crusts were
apparent over the medial aspect of the left upper lid margin. No intraoral, periungual, or
perianal abnormalities were noted. No hair abnormalities were appreciated.
Initial laboratory data included a complete blood count (CBC), chemistry profile, and
acanthotic epidermis. Foci of minimal spongiosis were noted. Superficially, the
keratinocytes were large and pale. Within the dermis, papillary dermal edema, scattered
extravasated erythrocytes, and a superficial, perivascular, mononuclear infiltrate were
noted.
Discussion
Kwashiorkor is a form of protein–energy malnutrition
where the caloric intake remains adequate in the face of
prolonged protein deficiency. It is most frequently
diagnosed in the pediatric population, when malnourishment causes a 20% to 40% decrease in expected body
weight with edema or hypoproteinemia. Classic cutaneous
manifestations include hypopigmentation and dry fissured
areas with an ‘‘enamel paint’’ appearance over locations
under pressure or with increased moisture.1 These areas
appear hyperpigmented in dark skin and red–purple in fair
skin. The lesions tend to extend peripherally, eventually
coalescing into widespread erosions with a waxy, ‘‘flaky
paint’’ appearance.2
There is a predilection for lesions to appear on limbs and
buttocks. Secondary colonization with Candida albicans or
bacterial infection may occur.3 Mucous membrane involvement, such as cheilitis and angular stomatitis, can be seen
in advanced disease. The hair may be sparse and dry. A
reddish tinge can be appreciated in patients with dark hair.
Intermittent episodes of insufficient protein intake can
cause bands of alternating light and dark hair known as
the ‘‘flag sign’’.4 The nails may appear thin and soft.5
Central nervous system effects include irritability and
apathy.
Total and partial gastrectomies have been performed for
various purposes, such as gastric carcinoma, gastric ulcers,
gastric angiomas, and weight control. The occurrence of
Figure 1 Sharply demarcated,
dusky red plaques with superficial
desquamation in a ‘‘cracked
enamel’’ configuration
© 1998 Blackwell Science Ltd
International Journal of Dermatology 1997, 37, 128–144
135
136
Cameo Kwashiorkor and zinc deficiency
Jaffe and Heymann
Figure 2 A biopsy showing dense
parakeratotic scale with an
irregularly acanthotic, minimally
spongiotic epidermis. Keratinocytes
appear large and pale. Papillary
dermal edema, scattered
extravasated erythrocytes and a
superficial, perivascular,
mononuclear infiltrate can be seen
malnutrition in long-term survivors of total or partial
gastrectomy has been well documented.6,7 Several investigators have noted a striking similarity of kwashiorkor to
zinc deficiency.3,8 Ulceration, edema, stunting, and wasting
have been observed in patients with low plasma zinc
concentrations. Diarrhea, hair fragility, and dyspigmentation, as well as an increased susceptibility to infection,
are also common features to both protein–energy malnutrition and zinc deficiency.9 The classic findings in kwashiorkor resemble those of acrodermatitis enteropathica. Golden
et al.10 reported a statistically significant response of
kwashiorkor skin lesions to the topical application of
zinc sulfate. They also concluded that, ‘‘low plasma zinc
concentrations previously found in malnourished children
with skin sores reflected actual zinc deficiency, and not a
spurious association caused by lowering of plasma zinc
binding sites or redistribution of zinc within the body.’’
The precise mechanisms by which zinc deficiency may be
associated with protein–energy malnutrition remained to
be defined.
Only a few reports exist of combined protein and zinc
deficiency in adults. In 1976 and 1978, Weismann et al.11,12
described two parallel cases of zinc deficiency associated
with chronic alcoholism, cirrhosis, pancreatitis and Billroth
II gastric resection. Low albumin levels were also noted.
The negative zinc balance was attributed to chronic alcoholism and cirrhosis. The patients’ skin improved rapidly
after oral zinc sulfate therapy, although relapses were
common. Another case from Weissman et al.11 displayed
zinc deficiency in a 28-year-old woman secondary to a
small-intestine bypass operation for obesity. She similarly
responded to zinc sulfate therapy; however, follow-up was
International Journal of Dermatology 1997, 37, 128–144
not obtained. In 1977, a similar kwashiorkor-like syndrome
was reported in a 6-week-old male infant who underwent
a necrotic bowel resection, although zinc levels were not
investigated.2 In 1979, a kwashiorkor-like zinc deficiency
syndrome was reported in a 26-year-old woman with
anorexia nervosa.3 She improved shortly after receiving
oral zinc sulfate and intravenous human albumin. This
case brought into question the true etiology of the skin
changes seen in classic Kwashiorkor, including hypoproteinemia and/or hypozincemia.
Our patient suffered a prolonged hospital course complicated by diarrhea, dehydration, and sepsis. Her skin lesions
improved within 1 week after receiving total parenteral
nutrition with zinc sulfate supplementation. One month
after initiation of therapy, her skin showed diffuse postinflammatory hyperpigmentation without erythema or
crusting. She is currently awaiting surgical evaluation for
a potentially curative bypass reversal. Several methods of
treatment for kwashiorkor-like illness following gastrectomy have been reported. Kumei et al.13 have shown that
elemental diets improve the overall condition of such
patients. A report by Kadowaki et al.14 detailed a reconstructive intestinal procedure providing the relief of symptoms over an 8-year follow-up period to a woman with
secondary kwashiorkor due to total gastrectomy.
Our case is the first documented kwashiorkor/zinc deficiency overlap following partial gastrectomy for obesity.
While other nutritional deficiencies (i.e. essential fatty acids,
other vitamins) certainly could have contributed to our
patient’s clinical presentation, they were, unfortunately,
not measured. The cases reported by Weissman et al.11,12
showed some similarities to our patient. The patients with
© 1998 Blackwell Science Ltd
Kural et al.
Cutaneous bronchogenic cysts Cameo
combined zinc and protein deficiencies in the setting of
chronic alcoholism, cirrhosis, and chronic pancreatitis after
gastric resection showed a probable mixed etiology. The
authors attributed these deficits to malabsorption and
poor nutrition from chronic alcoholism, cirrhosis, and
pancreatitis. Because our case was not complicated by
other variables, such as alcoholism and its sequelae, we
can hypothesize that the clinical presentation was at least
partly due to a kwashiorkor/zinc deficiency overlap following gastrectomy.
This report should serve to make physicians more aware
of the existence of multiple nutritional deficiencies in postgastrectomy patients, and the need to determine both zinc
and protein levels if suspicious skin lesions appear.
Acknowledgments
Dr Robert Gerard referred this patient to us and provided
clinical and laboratory data. Dr Roy L. Stern provided
photographs and a review.
References
1 Prendiville JS, Manfredi LN. Skin signs of nutritional
disorders. Semin Dermatol 1992; 11: 88–97.
2 Smith SZ. Skin changes in short-bowel syndrome. Arch
Dermatol 1977; 113: 657–659.
3 Esca SA, Brenner W, Mach K, Gschnait F. Kwashiorkorlike zinc deficiency syndrome in anorexia nervosa. Acta
Dermatol Venereol 1979; 59: 361–364.
4 McLaren DS. Skin in protein energy malnutrition. Arch
Dermatol 1987; 123: 1674–1676.
5 Williams CD. A nutritional disease of childhood
associated with a maize diet. Arch Dis Child 1933; 8: 423.
6 Adams JM. The clinical and metabolic consequences of
total gastrectomy. Scand J Gastroenterol 1967; 2: 137–
149.
7 Sasagawa T, Karasawa K, Ogoshi K, et al. The treatment
of secondary kwashiorkor after gastrectomy by per oral
administration of multiple amino acids. Acta Hepatol
Japonica 1968; 9: 53–57.
8 Sandstead HH. Protein Calorie Malnutrition. New York:
Academic Press, 1975: 213.
9 Golden BE, Golden MH. Plasma zinc and the clinical
features of malnutrition. Am J Clin Nutr 1979; 32: 2490–
2494.
10 Golden MHN, Golden BE, Jackson AA. Skin breakdown
in kwashiorkor responds to zinc. Lancet 1980; 1: 1256.
11 Weismann K, Wadskov S, Mikkelsen HI, et al. Acquired
zinc deficiency dermatotis in man. Arch Dermatol 1978;
114: 1509–1511.
12 Weismann K, Reed-Petersen J, Hjorth N, et al. Chronic
zinc deficiency syndrome in a beer drinker with a Billroth
II resection. Int J Dermatol 1976; 15: 757–761.
13 Kumei Y, Minemoto H, Ueda N, et al. A case study of
secondary kwashiorkor syndrome well treated with an
enteral alimentary diet. Tan to Sui (J Biliary Tract
Pancreas) 1982; 3: 1609–1614.
14 Kadowaki A, Tajima T, Kogure H, et al. Successful
surgical treatment of secondary kwashiorkor after total
gastrectomy: report of a case. Jpn J Surg 1995; 25: 548–
551.
Cameo
Cutaneous bronchogenic cysts
Yasemin Balsever Kural, MD, Selma Ergün, MD, Nesimi Büyükbabani, MD, Refika
Durmuşouǧlu, MD, and Nahide Onsun, MD
From the Vakif Gureba Hospital and
Istanbul Medical School, Istanbul,
Turkey
Case 1 A 13-year-old girl had a swelling and draining sinus on the suprasternal notch
Correspondence
Yasemin Balsever Kural,
Kaya Sultan Sok
Dumankaya Sitesi C
1C Blok No: 18
Kozyataǧi
Istanbul
Turkey
cm 3 2 cm) on the suprasternal notch, together with a sinus mea with a small amount of
mucoid secretion (Fig. 1).
Although a mediastinal mass was seen in the chest X-ray, ultrasound (US) and
MD
which had been present since infancy. The lesion had previously been treated with many
methods, but none had been successful. Clinically, there was a mobile cystic mass (3
magnetic resonance (MR) examination demonstrated that the lesion was a hyperplastic
thymus. No other abnormalities were found in the general physical and laboratory
examination of the patient.
The skin lesion was excised under local anesthesia. There was no evidence of
extension or connections to other structures or to deep tissues. The postoperative course
was uneventful and the patient has been free from recurrence.
© 1998 Blackwell Science Ltd
International Journal of Dermatology 1998, 37, 128–144
137
138
Kural et al.
Cameo Cutaneous bronchogenic cysts
Microscopic examination of the punch biopsy specimen performed on the cutaneous
cyst revealed skin structures and adjacent cystic space lined by ciliated pseudostratified
columnar epithelium (Fig. 2). The cyst epithelium contained many goblet cells intermingled
with ciliated columnar cells (Fig. 3). In the connective tissue surrounding the cystic cavity,
smooth muscle, cartilage, or thyroid tissue could not be identified. Based on these
histologic features, a diagnosis of bronchogenic cyst was made. Excisional biopsy
followed, and pathologic examination of the specimen confirmed the diagnosis.
Case 2 A 14-year-old boy had a draining sinus on the suprasternal notch which had been
present since 3 months of age. Drainage had been applied to this lesion 6 months
previously, as it was thought to be an infection. On close examination, a mobile cystic
mass (1.5 cm 3 2.5 cm) and a sinus mea were present on the suprasternal notch.
Physical and laboratory examination revealed no other abnormalities.
Total surgical excision of this skin lesion was performed under local anesthesia. During
the operation, a small amount of clear mucoid fluid was obtained from the cyst by lateral
compression; however, no evidence of extension or connections to other structures or to
deep tissues was present. The postoperative course was uneventful. The histologic
features of the second case were similar to the first.
Discussion
Cutaneous bronchogenic cysts (CBCs) are extremely rare
congenital anomalies; about 50 cases have been described
in the literature. In most cases, the lesions are noted shortly
after birth or in early childhood and present as a swelling
or draining sinus. The cysts are usually observed near the
suprasternal notch or manibrum sterni; they can also be
found in the neck, chin, base of the tongue, shoulder, and
scapular region.1–5
The origin and pathogenesis of CBCs are difficult to
explain. Cutaneous bronchogenic cysts are thought to arise
from congenital anomalous development of the tracheobronchial buds from the primitive foregut origin. Another
explanation is that a preformed cyst of the thoracic cavity
may be pinched off and then migrate to the cutaneous
tissues of the neck during the development of the tracheobronchial tree. Support for this theory of displacement is
offered by two cases reported by Fraga et al., in which a
cord-like connection arched from the extrathoracic cyst
around the suprasternal notch towards the mediastinum.1–3
Clinically, most patients have an asymptomatic soft mass
or draining sinus tract in the extrathoracic area noted in
infancy or childhood. The cyst predominates in boys over
girls by a ratio of almost 4 : 1.2
Although mucoepidermoid carcinoma arising from
bronchogenic cyst has been reported to be quite rare, it
emphasizes the importance of total surgical excision.6–8
The differential diagnosis includes cutaneous ciliated
cysts, thyroglossal duct cysts, branchial cysts, and teratoma.
Thyroglossal duct cysts are usually located on the midline of
the neck in the region of the hyoid bone; histologically,
International Journal of Dermatology 1998, 37, 128–144
they may be lined ciliated epithelium; they lack goblet cells.
Thyroid follicles are often observed in the surrounding connective tissues of thyroglossal duct cysts. Branchial cysts
are usually found on the lateral surface of the neck, and
histologically are characterized by prominent lymphoid tissues. Ciliated cystic lesions in male patients are distinguished
from some of the ciliated cysts found in female patients from
a consideration of the location e.g. vulvar cysts of urogenital
sinus origin, cutaneous endometriosis, and cutaneous ciliated cysts occuring on the lower extremities.6,9–11
In our two cases, CBCs are located on the midline of the
suprasternal notch. Swelling and drainage were observed
from the cysts periodically. Histologically, the cysts were
lined by ciliated pseudostratified columnar epithelial cells
Figure 1 Case 1: a swelling and draining sinus on the
suprasternal notch
© 1998 Blackwell Science Ltd
Kural et al.
Cutaneous bronchogenic cysts Cameo
Figure 2 Adjacent to skin surface on
the right, cystic structure lined by
columnar epithelium (hematoxylin
and eosin, 3 40)
Figure 3 High magnification of an
infolding of the inner lining of the
cyst epithelium showing ciliated
columnar cells and intermingled
goblet cells (hemetoxylin and eosin,
3 400)
interspersed with goblet cells; thyroid tissues could not be
identified. Based on these histologic features, the diagnosis of
CBC was made. No other complications in the postoperative
follow-up were seen.
The duration and location of the cyst and sinus
are important considerations in making an accurate
preoperative diagnosis of CBC. For the dermatologist,
CBC must be considered in the differential diagnosis of
cysts on the neck. Awareness of this lesion by surgeons
© 1998 Blackwell Science Ltd
in the differential diagnosis of masses or sinuses presenting
in the suprasternal region may prevent the incomplete
excision of components, which can extend deep into the
site of origin. The possibility of extension into the
mediastinum should be eliminated by evaluation of the
chest X-ray and, if necessary, by magnetic resonance
(MR). These assist in planning the operative approach.
The lesion should be excised totally to eliminate the
possibility of recurrence.
International Journal of Dermatology 1998, 37, 128–144
139
140
Tausch et al.
Clinical trial Itraconazole and terbinafine
References
1 Muramatsu T, Shrai T, Sakamato K. Cutaneous
bronchogenic cyst. Int J Dermatol 1990; 29: 143–144.
2 Pul N, Pul M. Bronchogenic cyst of the scapular area in
an infant: case report and review of the literature. J Am
Acad Dermatol 1994; 31: 120–122.
3 Miller OF, Tyler W. Cutaneous bronchogenic cyst with
papilloma and sinus presentation. J Am Acad Dermatol
1984; 11: 367–371.
4 Tressner NJ, Dahms B, Bemer JJ. Cutaneous
bronchogenic cyst of the back. A case report and review
of the literature. Pediatr Pathol 1994; 14: 207–212.
5 Boue DR, Smith GA, Krous HF. Lingual bronchogenic
cyst in a child. An unusual site of presentation. Pediatr
Pathol 1994; 14: 201–205.
6 Tyson RW, Groft DB. An unusual lateral neck cyst with
7
8
9
10
11
the combined features of a bronchogenic thyroglossal
and branchial cleft origin. Pediatr Pathol 1993; 13: 567–
572.
Van der Putte SC, Toonstra J. Cutaneous bronchogenic
cyst. J Cutan Pathol 1985; 12: 404–409.
Matsuda N, Marimoto K, Tancha K, et al. A case of
bronchogenic cyst at the anterior chest wall. Nippon
Geka Gakkai Zasshi 1994; 97: 794–796.
Bagwell LCE, Schiffman RJ. Subcutaneous bronchogenic
cysts. J Pediatr Surg 1988; 23: 993–995.
Farmer ER, Helwig EB. Cutaneous ciliated cyst. Arch
Dermatol 1978; 114: 70–73.
Coleman WR, Homer RS, Kaplan RP. Branchial cleft
heterotopia of the lower neck. J Cutan Pathol 1989; 16:
353–358.
Clinical trial
Short-term itraconazole versus terbinafine in the treatment of
tinea pedis or manus
Irene Tausch, MD, Jacques Decroix, MD, Zenon Gwiezdzinski MD,
Stawomir Urbanowski, MD, Eugeniusz Baran, MD, Marek Ziarkiewicz, MD,
Gary Levy, MD, and Amalia Del Palacio, MD
From the Department of
Dermatology, Humboldt University,
Berlin and Bioskin Institute for
Dermatological Research, Hamburg,
Germany; Dermatology Clinic,
Mouscron, Belgium; Dermatology
Clinic, Bydgoszcz and Dermatology
Clinic, Wroclaw, Poland; Dermatology
Clinic, Morningside, Gauteng, South
Africa; and Department of
Microbiology, Hospital 12 de Octubre,
Madrid, Spain
Correspondence
Irene Tausch, MD
Bioskin Institute for Dermatological
Research and Development GmbH
Poppenbütteler Bogen 25
22399 Hamburg
Germany
A total of 304 patients with a clinical diagnosis of palmar-type tinea pedis or manus and a
positive mycologic examination were recruited into this double-blind, randomized,
multicenter, phase III study. Patients were randomized to receive either oral itraconazole
200 mg twice daily (in the morning and evening) for 7 days, followed by placebo for 7
days (n 5 153), or placebo in the morning and oral terbinafine 250 mg in the evening for
14 days (n 5 151).
At the first visit and 1, 2, and 6 weeks after the start of the study, signs and symptoms
were assessed clinically, and scales were taken for mycologic assessments (microscopy
and culture). At weeks 1, 2, and 6, the effectiveness of therapy was evaluated globally
and given a rating of healed (absence of signs and symptoms), marked improvement
(ù 50% clinical improvement), considerable residual lesions (, 50% clinical
improvement), no change, or worsened. The primary efficacy parameter was the
mycologic cure rate at the follow-up end-point (week 6).
The tolerability of the study medications was assessed at weeks 1 and 2. Adverse
events were recorded at weeks 1, 2, and 6. Routine hematologic and biochemical tests
were performed at the start of the study and after 1 week of treatment.
No significant differences were seen in the baseline patient characteristics between the
two groups. The rate of mycologic cure (negative microscopy and culture test result) was
79% in the itraconazole group and 80% in the terbinafine group at the follow-up end-point.
The analysis of the 90% confidence interval for the difference between the treatment
groups (–7.1, 5.4) and the outcome of the Blackwelder test (for two one-sided tests,
P 5 0.013 and P 5 0.029) showed the two treatments to be equivalent.
International Journal of Dermatology 1998, 37, 128–144
© 1998 Blackwell Science Ltd
Tausch et al.
The Janssen Research Foundation,
Beerse, Belgium provided support.
The following investigators
participated in the study: J. Decroix
(Belgium); A. Aenstoots, J. Dinu,
D. Krausch, X. Kuehn,
E. Morgenstern, D. Petzoldt, M.
Schnicke, X. Schramm, R. Stadler,
I. Tausch, J. Teichmann, T Walther,
W. Wehrmann, H. Wetz, X. Wokalck
(Germany); E. Panconesi, M. Papini
(Italy); E. Baran, Z. Gwiezdzinski, T.
Kotodziej, S. Urbanowski,
M. Ziarkiewicz (Poland); C. Keyzer,
G. Levy, Y. Omar, D. Presbury,
W. Sinclair, J. Van Heerden, S. Voget,
R. Weiss (South Africa); A. Del
Palacio, A. Tuneu (Spain).
Itraconazole and terbinafine Clinical trial
The results of the global evaluations of the efficacy in the two treatment groups are
shown in Table 1. The rate of clinical response (healed or markedly improved) was 93%
in the itraconazole group and 91% in the terbinafine group at the follow-up end-point. The
analysis of the 90% confidence interval for the difference between the two groups (–2.5,
5.7) and the outcome of the Blackwelder test (for two one-sided tests, P 5 0.004 and
P , 0.001) showed the two treatments to be equivalent. The severity of the clinical signs
and symptoms decreased from the baseline to the treatment end-point and from the
treatment end-point to the follow-up end-point in both groups.
At the double-blind treatment period end-point (week 2), the tolerability of the study
medication was rated as very good or good in more than 97% of patients. During
treatment, 21 of 153 patients (14%) in the itraconazole group and 28 of 151 patients
(19%) in the terbinafine group reported adverse events. During follow-up, one patient in
the itraconazole group and two in the terbinafine group reported adverse events. The
most frequent events were headache, abdominal pain, nausea, vomiting, and
hypertriglyceridemia.
Two patients in the itraconazole group and four in the terbinafine group withdrew
because of adverse events. Severe adverse events were reported by one patient in the
itraconazole group and five in the terbinafine group. Serious adverse events were
reported by two patients in the terbinafine group, although these were probably not drug
related. No clinically relevant changes in laboratory variables were observed.
14 days, in patients with tinea pedis or manus. The results
showed that, at the follow-up end-point, both mycologic
cure rates and clinical response rates were statistically
equivalent in the two treatment groups. The cure rates
were similar to those reported previously with terbinafine
250 mg/day for 2–6 weeks4 or itraconazole 100 mg/day
for 4 weeks,5,6 and were consistent with the results of a
preliminary clinical trial of itraconazole 200 mg twice daily
for 1 week.7
Overall, both trial medications were well tolerated, with
the incidences of adverse events within the ranges of
previous values for terbinafine4,8 and itraconazole.3,5,9
The short treatment schedule of itraconazole 400 mg/
day for 7 days has the advantages of reducing the time
during which the patient is at risk of experiencing sideeffects and of being generally more convenient for the
Discussion
Pharmacokinetic studies have shown that the triazole antifungal agent itraconazole has a high affinity for the stratum
corneum and can persist in this tissue for up to 4 weeks
after the discontinuation of therapy (100 mg/day for 4
weeks).1,2 This pharmacokinetic profile has led to the
development of short itraconazole treatment courses, such
as 400 mg/day for 7 days and 100 mg/day for 15 or 30
days, which have been shown to be effective in the treatment
of dermatophyte infections of the skin (J. Schuller, personal
communication).3
The therapeutic effect, tolerability, and safety of a shortterm itraconazole schedule (200 mg twice daily for 7 days)
was compared in the present study with those of a standard
recommended treatment, terbinafine 250 mg once daily for
Table 1 Global evaluation of efficacy
Patients (%)
End-point of treatment
Healed
Markedly improved
Considerable residual lesions
No change
Worse
© 1998 Blackwell Science Ltd
End-point of follow-up
Itraconazole
(n 5 151)
Terbinafine
(n 5 150)
Itraconazole
(n 5 143)
Terbinafine
(n 5 140)
13
61
20
6
0
11
55
27
7
0
58
35
6
1
0
54
37
5
4
0
International Journal of Dermatology 1998, 37, 128–144
141
142
Maloney et al.
Clinical trial Clobetasol propionate
patient than long-term schedules, thus improving the likelihood that the patient will complete the full course of
treatment.
Conclusions
The results of this trial showed that itraconazole 400 mg/
day for 7 days and terbinafine 250 mg/day for 14 days are
equally effective in the treatment of tinea pedis or tinea
manus. Itraconazole and terbinafine were equally well
tolerated by patients. Itraconazole had a slightly better
safety record in terms of severe or serious adverse events;
however, the overall number of patients with severe or
serious adverse events was too small to confirm or refute
this statistically. The treatment regimen of itraconazole 400
mg/day for 7 days can be recommended for patients with
tinea pedis or tinea manus.
References
1 Heykants J, Michiels M, Meuldermans W, et al. The
pharmacokinetics of itraconazole in animals and man:
an overview. In: Fromtling RA, ed. Recent Trends in the
Discovery, Development and Evaluation of Antifungal
Agents. Barcelona, Spain: JR Prous Science Publishers,
1987: 223–249.
2 Cauwenbergh G, Degreef H, Heykants J, et al.
Pharmacokinetic profile of orally administered
itraconazole in human skin. J Am Acad Dermatol 1988;
18: 263–269.
3 De Doncker P, Cauwenbergh G. Management of fungal
skin infections with 15 days itraconazole treatment: a
worldwide review. Br J Clin Pract 1990; 44: 118–122.
4 Villars VV, Jones TC. Special featuresof the clinical use
of oral terbinafine in the treatment of fungal diseases. Br
J Dermatol 1992; 126(Suppl. 39): 61–69.
5 Roseeuw D, Willemsen M, ‘T Knit R, et al. Itraconazole
in the treatment of superficial mycoses — a double-blind
study vs. placebo. Clin Exp Dermatol 1990; 15:
101–104.
6 Cauwenbergh G, de Doncker P, Stoops K, et al.
Itraconazole in the treatment of human mycoses: review
of three years of clinical experience. Rev Infect Dis
1987; 9: 146–152.
7 Decroix J. Tinea pedis (moccasin-type) treated with
itraconazole. Int J Dermatol 1995; 34: 122–124.
8 Arenas R, Dominguez-Cherit J. Open randomized
comparison of itraconazole versus terbinafine in
onychomycosis. Int J Dermatol 1995; 34: 138–143.
9 De Beule K, Lubin G, Cauwenbergh G. Safety aspects of
itraconazole therapy in vaginal candidosis,
dermatomycosis and onychomycosis: a review. Curr
Ther Res 1991; 49: 814–822.
Clinical trial
Clobetasol propionate emollient 0.05% in the treatment of
atopic dermatitis
J. Michael Maloney, MD, Manuel R. Morman, PhD, MD, Daniel M. Stewart, DO,
Michael D. Tharp, MD, Jeanine Johnson Brown, PharmD, and Rukmini Rajagopalan,
DrPH, MBA, RN
From Cherry Creek Dermatology,
Denver, Colorado; Private Practice,
Rutherford, New Jersey; Midwest
Cutaneous Research Corp., Clinton
Township, Michigan; University of
Pittsburgh School of Medicine,
Pittsburgh, Pennsylvania; and Glaxo
Dermatology, Research Triangle Park,
North Carolina
A 4-week, double-blind, randomized clinical trial, comparing the efficacy and safety of
clobetasol propionate emollient cream 0.05% and its vehicle, was conducted at four
private dermatology clinics in 81 non-hospitalized patients (ù 12 years old) with
moderate-to-severe atopic dermatitis covering 2% or more of their body surface. All
patients had at least one lesion 2 cm or more in diameter. Three signs/symptoms of target
lesions (erythema, pruritus, and induration/papulation) were scored by investigators on a
scale of 0–3 (in 0.5-point increments; 0 5 absent, 1 5 mild, 2 5 moderate, and 3 5
severe); the total of the three scores had to be ù 6 for patients to qualify for study entry.
Patients were excluded if they were immunocompromised, pregnant, or nursing; had skin
atrophy, telangiectasia or striae in skin areas to be treated; or had received topical
treatments for atopic dermatitis within 1 week prestudy, intramuscular triamcinolone within
6 weeks prestudy, or long-term systemic corticosteroid usage within 6 months prestudy.
International Journal of Dermatology 1998, 37, 128–144
© 1998 Blackwell Science Ltd
Maloney et al. Clobetasol propionate
Correspondence
Jeanine Johnson Brown, PharmD
Glaxo Dermatology
A Division of Glaxo Wellcome Inc.
Five Moore Drive
Research Triangle Park
NC 27709
Clinical trial
Patients were randomized in a 1 : 1 ratio to receive either clobetasol propionate
emollient 0.05% twice daily (n 5 41), or the emollient vehicle twice daily (n 5 40), for 4
weeks. A fingertip unit, equaling approximately 0.5 g in males and 0.43 g in females
(enough to cover approximately 2% of the body), was used to measure and apply a thin
film of study drug to the affected areas.
The efficacy was evaluated by investigators and patients on days 4, 8, 15, and 29 after
initiation of therapy, and 2 weeks after the end of treatment (day 43). Investigators
performed a physician’s gross assessment based on the percentage improvement of the
target lesion. They also rated changes from baseline in mean severity scores for six
individual signs/symptoms (erythema, pruritus, induration/papulation, lichenification,
erosion/oozing/crusting, and scaling/dryness) and for total signs/symptoms according to
the severity scoring system described above. Patients rated their response to treatment
as excellent, good, fair, poor, or worse. Laboratory assessments were made on days 15,
29, and (if necessary) day 43.
Results
Eighty-one patients were initially enrolled into the study
(41 treated with clobetasol propionate and 40 with vehicle).
There were no significant differences between the
treatment groups in any of the demographic parameters
or baseline medical history, physical examination results,
location of the atopic dermatitis lesions, or concurrent
drugs or illnesses. Thirty-seven patients (90%) in the
clobetasol group and 24 (60%) of the vehicle group
completed all 43 days of the study. No withdrawals in the
clobetasol group were for treatment failure, whereas 10
patients (25%) in the vehicle group withdrew for this
reason.
Clobetasol propionate emollient produced significantly
(P ø 0.006) greater improvement than the vehicle by day
4 with respect to total severity scores (Fig. 1) and scores
Figure 1 Investigator-rated changes in mean severity scores
for total signs/symptoms. *Evaluation times when clobetasol
emollient group had significantly lower scores than the
vehicle group.
© 1998 Blackwell Science Ltd
for erythema, pruritus, induration/papulation, and scaling/
dryness, and by day 8 with respect to severity scores for
lichenification
and
erosion/oozing/crusting.
This
significantly greater improvement than the vehicle was
maintained for all individual and total symptom/sign scores
throughout the rest of the treatment period, and during
the 2 weeks post-treatment, except at day 43 for erosion/
oozing/crusting. Physician gross assessment ratings (Fig.
2a) and patient self-assessment ratings (Fig. 2b) for
clobetasol propionate were superior (P , 0.006 and P ,
0.002, respectively) by day 4 to those of the vehicle, and
remained so during the rest of the treatment and posttreatment periods. More clobetasol-treated patients were
assessed as good, excellent, or cleared at both day 29 (82%
vs. 29%) and day 43 (78% vs. 33%) in the physician’s
gross assessment ratings and as good or excellent at day
29 (84% vs. 29%) and day 43 (78% vs. 42%) in the
patient self-assessments.
Clobetasol propionate emollient and vehicle were equally
well tolerated, with only mild drug-related adverse events
noted in one clobetasol-treated patient (pruritus, burning/
stinging) and in two vehicle-treated patients (skin atrophy,
pruritus). No skin atrophy was observed in the clobetasol
emollient group. No significant differences between treatment groups were noted in the number of patients who
experienced a 50% decrease or more in serum cortisol
concentrations (15% with clobetasol propionate vs. 11%
with vehicle, P 5 0.737). Three (8%) of the patients
treated with clobetasol propionate had serum cortisol
concentrations decreased below the lower limit of the
normal range (5–18 µg/dL) during the study compared
with none in the vehicle group (P 5 0.240). Two of these
three patients had baseline cortisol concentrations at the
low end of the normal range (5 and 7 µg/dL, respectively)
and one used 240 g of study drug during the 4-week
International Journal of Dermatology 1998, 37, 128–144
143
144
Maloney et al.
Clinical trial Clobetasol propionate
treatment), and by day 43 in the third patient. The decreases
in cortisol concentrations were considered too small to be
clinically significant.
Discussion
Figure 2 Physician’s gross assessment (a) and patient’s self-
assessment (b) of target lesion response; C, clobetasol
emollient; V, vehicle; *evaluation times when clobetasol
emollient group had significantly lower scores than the
vehicle group.
treatment period instead of just 200 g as defined by the
protocol. Serum cortisol concentrations returned to normal
by day 29 in two patients (despite the continuation of
International Journal of Dermatology 1998, 37, 128–144
The results of this study demonstrate that clobetasol propionate emollient 0.05%, applied twice daily for 4 weeks, is
effective and well tolerated in the treatment of moderateto-severe atopic dermatitis. The improvement observed at
the end of the first 2 weeks of treatment is not only safely
sustained during the subsequent 2 weeks and 2 posttreatment weeks, but may actually progress, as confirmed
in all physician and patient ratings. Unlike other formulations of high-potency topical corticosteroids administered
for longer than 2 weeks,1 the emollient formulation of
clobetasol propionate, administered continuously for 4
weeks, appears unlikely to cause skin atrophy or clinically
significant hypothalamus–pituitary–adrenal (HPA)-axis
suppression.
Only one patient (2.5%) developed subnormal plasma
cortisol concentrations (, 5 µg/dL) after receiving the total
dose of 200 g prescribed by the protocol. In an earlier study
evaluating clobetasol emollient over a 2-week treatment
period, one of 52 (2%) patients with eczema likewise
developed subnormal cortisol concentrations.2 Two-week
clinical trials supporting the New Drug Applications for
the ointment, cream, gel, or scalp solution indicated that
subnormal serum cortisol concentrations occur with a 4–
15% incidence.2 Thus, HPA-axis suppression with a 4week regimen of clobetasol propionate emollient 0.05%
may be less likely, or certainly no more frequent, than such
suppression
occurring
with
other
topical
clobetasol propionate formulations used for 2 weeks.
References
1 Marks R. Adverse side effects from the use of topical
corticosteroids. In: Maibach HI, Surber C, eds. Topical
Corticosteroids. Basel, Switzerland: S. Karger, 1992:
170–183.
2 Data on file, Glaxo Dermatology, Glaxo Wellcome Inc.,
Research Triangle Park, North Carolina.
© 1998 Blackwell Science Ltd